urmjУральский медицинский журналUral Medical Journal2949-4389Ural State Medical University10.52420/2071-5943-2021-20-1-89-96urmj-764Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSПептидный гормон релаксин: от молекулярных эффектов к клиническим результатамPeptide hormone relaxin: from molecular effects to clinical resultsПрохороваО. В.ProkhorovaO. V.

Прохорова Ольга Валентиновна, к.м.н., доцент

г. Екатеринбург

Olga V. Prokhorova, PhD, associate professor

Ekaterinburg

Prokhorova-ov@yandex.ruОлинаА. А.OlinaA. A.

Олина Анна Александровна, д.м.н., профессор

г. Санкт-Петербург; г. Пермь

Anna A. Olina, PhD, professor

Saint Petersburg; Perm

olina29@mail.ruТолибоваГ. Х.TolibovaG. Kh.

Толибова Гулрухсор Хайбуллоевна, д.м.н.

г. Санкт-Петербург

Gulrukhsor Kh. Tolibova, PhD

Saint Petersburg

gulyatolibova@yandex.ruТральТ. Г.TralT. G.

Траль Татьяна Георгиевна, к.м.н.

г. Санкт-Петербург

Tatyana G. Tral, PhD

Saint Petersburg

ttg.tral@yandex.ruФГБОУ ВО «Уральский государственный медицинский университет» Минздрава РоссииРоссияUral State Medical UniversityRussian FederationФГБНУ «Научно-исследовательский институт акушерства, гинекологии и репродуктологии им. Д.О. Отта»; ФГБОУ ВО «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Минздрава России; ФГБОУ ВО «Пермский государственный медицинский университет имени академика Е.А. Вагнера» Минздрава РоссииРоссияD.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology; North-Western State Medical University named after I.I. Mechnikov; E.A. Wagner Perm State Medical UniversityRussian FederationФГБНУ «Научно-исследовательский институт акушерства, гинекологии и репродуктологии им. Д.О. Отта»РоссияD.O. Ott Research Institute of Obstetrics, Gynecology and ReproductologyRussian Federation2021120720212018996Copyright © Прохорова О.В., Олина А.А., Толибова Г.Х., Траль Т.Г., 20212021Прохорова О.В., Олина А.А., Толибова Г.Х., Траль Т.Г.Prokhorova O.V., Olina A.A., Tolibova G.K., Tral T.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.umjusmu.ru/jour/article/view/764Введение

Введение. Пептидный гормон релаксин, вырабатывающийся клетками желтого тела при беременности и вне ее, обладает огромным количеством клинически значимых эффектов, опосредуя многие биологические механизмы, включая антифиброзное, вазодилатирующее, ангиогенное, противовоспалительное и антиапоптотическое действие.

Цель исследования

Цель исследования: на основе изучения современных литературных данных провести анализ результатов научных исследований, представляющих актуальную систему взглядов на физиологические и патофизиологические эффекты релаксина.

Материалы и методы

Материалы и методы. Проведено изучение научных публикаций за период с 2005 по 2020 годы в базах данных PubMed, Elibrary по ключевым словам relaxin, pregnancy, relaxin signaling pathway, reproductive system, extracellular matrix. Результаты и их обсуждение. Изучение современных взглядов на физиологию релаксина показало, что этот гормон опосредует свои эффекты путем связывания со специфическим рецептором RXFP1, локализованным в большом количестве репродуктивных и непродуктивных тканей. Показано, что релаксин выполняет множество функций, связанных с ремоделированием внеклеточного матрикса и сосудистой сети. Основные утеротропные эффекты данного пептида включают стимуляцию роста и васкуляризацию матки, ремоделирование компонентов внеклеточного матрикса и регулирование фактора роста эндотелия сосудов при подготовке к имплантации.

Заключение

Заключение. Произошедший в течение последнего десятилетия прогресс в понимании биохимии гормона релаксина лег в основу более глубокого проникновения во все многообразие его физиологических ролей. Участие релаксина в механизмах расслабления миометрия при беременности, ремоделировании соединительной ткани органов-мишеней в антенатальном периоде повышает его потенциальную клиническую значимость. Перспектива возможного терапевтического применения препаратов релаксина при стимулировании антенатальной трансформации шейки матки, экстракорпоральном оплодотворении, терапии преэклампсии, острой сердечной недостаточности и ишемии миокарда превращает его в потенциальное терапевтическое средство при указанных патологических состояниях.

Introduction

Introduction. The peptide hormone relaxin, which is produced by cells of the corpus luteum during and outside pregnancy, has a huge number of clinically significant effects, mediating many biological mechanisms, including antifibrotic, vasodilatory, angiogenic, anti-inflammatory and antiapoptotic effects.

Purpose of the study

Purpose of the study: based on the study of modern literature data, to analyze the results of scientific research, representing the current system of views on the physiological and pathophysilogical effects of relaxin.

Materials and methods

Materials and methods. A study f scientific publications for the period from 2005 to 2020 in e PubMed and Elibrary databases was carried out using the keywords: relaxin, pregnancy, relaxin signaling pathway, reproductive system, extracellular matrix.

Results and Discussion

Results and Discussion. The study of modern views on the physiology of relaxin has shown that this hormone mediates its effects by binding to the specific receptor RXFP1, which is localized in a large number of reproductive nonproductive tissues. Relaxin performs many functions related to the remodeling of the extracellular matrix and vasculature. The main uterotropic effects of this peptide include stimulation of growth and vascularization of the uterus, remodeling of extracellular matrix components, and regulation of vascular endothelial growth factor in preparation for implantation.

Conclusion

Conclusion. The progress of the last decade in understanding the biochemistry of the hormone relaxin has formed the basis for a deeper penetration into all the variety of its physiological roles. The participation of relaxin in the mechanisms of relaxation of the myometrium during pregnancy, remodeling of the connective tissue of target organs in the antenatal period creases its potential clinical significance. The prospect of a possible therapeutic use of relaxin preparations in stimulating antenatal transformation of the cervix, in vitro fertilization, therapy of preeclampsia, acute heart failure and myocardial ischemia turns it into a potential therapeutic agent for these pathological conditions.

релаксинбеременностьрепродуктивная системавнеклеточный матриксrelaxinpregnancyreproductive systemextracellular matrixReferencesHisaw, F. L. Experimental relaxation of the pubic ligament of the guinea pig // Proc. Soc. Exp. Biol. Med. – 1926. – Vol. 23. – Р. 661-663.Hisaw, F. L. Experimental relaxation of the pubic ligament of the guinea pig // Proc. Soc. Exp. Biol. Med. – 1926. – Vol. 23. – Р. 661-663.Friedman, A. Remembrance: the contributions of Frederick Hisaw // J. Clin. Endocrinol. Metab2003. – № 88. – Р. 524–527.Friedman, A. Remembrance: the contributions of Frederick Hisaw // J. Clin. Endocrinol. Metab2003. – № 88. – Р. 524–527.Sherwood, O. D. Relaxin's physiological roles and other diverse actions // Endocr Rev. – 2004. – № 25. –Р. 205–234.Sherwood, O. D. Relaxin's physiological roles and other diverse actions // Endocr Rev. – 2004. – № 25. –Р. 205–234.International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides / Bathgate R. A., Ivell R., Sanborn B. M. [et al.] // Pharmacol. Rev. – 2006. – № 58. – Р. 7-31.International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides / Bathgate R. A., Ivell R., Sanborn B. M. [et al.] // Pharmacol. Rev. – 2006. – № 58. – Р. 7-31.The relaxin receptor as a therapeutic target - perspectives from evolution and drug targeting / Bathgate R.A.D., Kocan M., Scott D.J. [et al.] // Pharmacol. Ther. – 2018. – № 187. – Р. 114-132.The relaxin receptor as a therapeutic target - perspectives from evolution and drug targeting / Bathgate R.A.D., Kocan M., Scott D.J. [et al.] // Pharmacol. Ther. – 2018. – № 187. – Р. 114-132.The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors / Alexander S. P. H., Davenport A. P., Kelly E. [et al.] // Br. J. Pharmacol. – 2015. – № 172. – Р. 5744-5861.The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors / Alexander S. P. H., Davenport A. P., Kelly E. [et al.] // Br. J. Pharmacol. – 2015. – № 172. – Р. 5744-5861.Structure of a genomic clone encoding biologically active human relaxin / Hudson P., Haley J., John M. [et al.] // Nature. – 1983. – № 301. – Р. 628-631.Structure of a genomic clone encoding biologically active human relaxin / Hudson P., Haley J., John M. [et al.] // Nature. – 1983. – № 301. – Р. 628-631.Cloning of a cDNA for a novel insulin-like peptide of the testicular Leydig cells / Adham I. M., Burkhardt E., Benahmed M. [et al.] // J. Biol. Chem. – 1993. – № 268. – Р. 26668–26672.Cloning of a cDNA for a novel insulin-like peptide of the testicular Leydig cells / Adham I. M., Burkhardt E., Benahmed M. [et al.] // J. Biol. Chem. – 1993. – № 268. – Р. 26668–26672.Relaxin family peptides: structure–activity relationship studies / Patil N. A., Rosengren K. J., Separovic F. [et al.] // British Journal of Pharmacology. – 2017. – Vol. 174 (10). – Р. 950-961.Relaxin family peptides: structure–activity relationship studies / Patil N. A., Rosengren K. J., Separovic F. [et al.] // British Journal of Pharmacology. – 2017. – Vol. 174 (10). – Р. 950-961.Understanding Relaxin Signalling at the Cellular Level / Valkovic A. L., Bathgate R. A., Samuel C. S. [et al.] // Mol. Cell. Endocrinol. – 2019. – № 487. – Р. 24-33.Understanding Relaxin Signalling at the Cellular Level / Valkovic A. L., Bathgate R. A., Samuel C. S. [et al.] // Mol. Cell. Endocrinol. – 2019. – № 487. – Р. 24-33.Peptide Hormone Relaxin: From Bench to Bedside / Jelinic M., Marshall S. A., Stewart D. [et al.] // Am. J. Physiol. Regul. Integr. Comp. Physiol. – 2018. – Vol. 314 (6). – Р. R753-R760.Peptide Hormone Relaxin: From Bench to Bedside / Jelinic M., Marshall S. A., Stewart D. [et al.] // Am. J. Physiol. Regul. Integr. Comp. Physiol. – 2018. – Vol. 314 (6). – Р. R753-R760.The Actions of Relaxin on the Human Cardiovascular System / Sarwar M., Du X. J., Dschietzig T. B. [et al.] // Br. J. Pharmacol. – 2017. – Vol. 174 (10). – Р. 933-949.The Actions of Relaxin on the Human Cardiovascular System / Sarwar M., Du X. J., Dschietzig T. B. [et al.] // Br. J. Pharmacol. – 2017. – Vol. 174 (10). – Р. 933-949.Relaxin' the Heart: A Novel Therapeutic Modality / Raleigh J. M., Toldo S., Das A. [et al.] // J. Cardiovasc. Pharmaco. l Ther. – 2016. – Vol. 21 (4). Р. 353-62.Relaxin' the Heart: A Novel Therapeutic Modality / Raleigh J. M., Toldo S., Das A. [et al.] // J. Cardiovasc. Pharmaco. l Ther. – 2016. – Vol. 21 (4). Р. 353-62.Martin, B. Cardioprotective Actions of Relaxin / B. Martin, G. Romero, G. Salama // Mol. Cell. Endocrinol. – 2019. – № 487. – Р. 45-53.Martin, B. Cardioprotective Actions of Relaxin / B. Martin, G. Romero, G. Salama // Mol. Cell. Endocrinol. – 2019. – № 487. – Р. 45-53.Therapeutic effects of serelaxin in acute heart failure / Du X. J., Hewitson T. D., Nguyen M. N. [et al.] // Circ. J. – 2014. – № 78. – Р. 542–552.Therapeutic effects of serelaxin in acute heart failure / Du X. J., Hewitson T. D., Nguyen M. N. [et al.] // Circ. J. – 2014. – № 78. – Р. 542–552.Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies / Rojko J. L., Evans M. G., Price S. A. [et al.] // Toxicol. Pathol. – 2014. – № 42. – Р. 725-764.Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies / Rojko J. L., Evans M. G., Price S. A. [et al.] // Toxicol. Pathol. – 2014. – № 42. – Р. 725-764.Serelaxin: a novel therapeutic for vascular diseases / Leo C. H., Jelinic M., Ng H. H. [et al.] // Trends Pharmacol. Sci. – 2016. – № 37. – Р. 498–507.Serelaxin: a novel therapeutic for vascular diseases / Leo C. H., Jelinic M., Ng H. H. [et al.] // Trends Pharmacol. Sci. – 2016. – № 37. – Р. 498–507.A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure / Ponikowski P., Mitrovic V., Ruda M. [et al.] // Eur. Heart. J. – 2014. – № 35. – Р. 431-441.A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure / Ponikowski P., Mitrovic V., Ruda M. [et al.] // Eur. Heart. J. – 2014. – № 35. – Р. 431-441.Unemori, E. Serelaxin in clinical development: past, present and future // Br. J. Pharmacol. – 2017. – № 174. – Р. 921-932.Unemori, E. Serelaxin in clinical development: past, present and future // Br. J. Pharmacol. – 2017. – № 174. – Р. 921-932.Does serelaxin treatment alter passive mechanical wall properties in small resistance arteries? / Jelinic M., Kahlberg N., Parry L. J. [et al.] // Microcirculation. – 2016. – № 23. – Р. 631–636.Does serelaxin treatment alter passive mechanical wall properties in small resistance arteries? / Jelinic M., Kahlberg N., Parry L. J. [et al.] // Microcirculation. – 2016. – № 23. – Р. 631–636.RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial / Teerlink J. R., Cotter G., Davison B. A. [et al.] // Lancet. – 2013. – № 381. – Р. 29-39.RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial / Teerlink J. R., Cotter G., Davison B. A. [et al.] // Lancet. – 2013. – № 381. – Р. 29-39.Teerlink, J. R. RELAXin in Acute Heart Failure-2 -RELAX-AHF-2. – Url: http://www.acc.org/latest-in-cardiology/clinical-trials/2017/05/07/16/09/relax-ahf-2.Teerlink, J. R. RELAXin in Acute Heart Failure-2 -RELAX-AHF-2. – Url: http://www.acc.org/latest-in-cardiology/clinical-trials/2017/05/07/16/09/relax-ahf-2.Relaxin protects against renal ischemia–reperfusion injury / Yoshida T., Kumagai H., Kohsaka T. [et al.] // Am. J. Physiol. Renal. Physiol. – 2013. – № 305. – Р. 1169-1176.Relaxin protects against renal ischemia–reperfusion injury / Yoshida T., Kumagai H., Kohsaka T. [et al.] // Am. J. Physiol. Renal. Physiol. – 2013. – № 305. – Р. 1169-1176.Hepatic fibrosis: Concept to treatment / Trautwein C., Friedman S. L., Schuppan D. [et al.] // J. Hepatol. – 2015. – № 62. – 1-24.Hepatic fibrosis: Concept to treatment / Trautwein C., Friedman S. L., Schuppan D. [et al.] // J. Hepatol. – 2015. – № 62. – 1-24.Anti-fibrotic Actions of Relaxin / Samuel C. S., Royce S. G., Hewitson T. D. [et al.] // Br. J. Pharmacol. – 2017. – Vol. 174 (10). – Р. 962-976.Anti-fibrotic Actions of Relaxin / Samuel C. S., Royce S. G., Hewitson T. D. [et al.] // Br. J. Pharmacol. – 2017. – Vol. 174 (10). – Р. 962-976.Conrad, K. P. Effects of relaxin on arterial dilation, remodeling, and mechanical properties / Conrad K. P., Shroff S. G. // Curr. Hypertens. Rep. – 2011. – № 13. – Р. 409-420.Conrad, K. P. Effects of relaxin on arterial dilation, remodeling, and mechanical properties / Conrad K. P., Shroff S. G. // Curr. Hypertens. Rep. – 2011. – № 13. – Р. 409-420.Relaxin protects rat lungs from ischemia-reperfusion injury via inducible NO synthase: role of ERK-1/2, PI3K, and forkhead transcription factor FKHRL1 / Alexiou K., Wilbring M., Matschke K. [et al.] // PLoS One. – 2013. – № 8. – Р. e75592–e75592.Relaxin protects rat lungs from ischemia-reperfusion injury via inducible NO synthase: role of ERK-1/2, PI3K, and forkhead transcription factor FKHRL1 / Alexiou K., Wilbring M., Matschke K. [et al.] // PLoS One. – 2013. – № 8. – Р. e75592–e75592.Conrad, K. P. Maternal Vasodilation in Pregnancy: The Emerging Role of Relaxin // Am. J. Physiol. Regul. Integr. Comp. Physiol. – 2011. – Vol. 301 (2). – Р. R267-75.Conrad, K. P. Maternal Vasodilation in Pregnancy: The Emerging Role of Relaxin // Am. J. Physiol. Regul. Integr. Comp. Physiol. – 2011. – Vol. 301 (2). – Р. R267-75.Conrad, K. PEmerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia // Semin. Nephrol. – 2011. – № 31 (1). – 15-32.Conrad, K. PEmerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia // Semin. Nephrol. – 2011. – № 31 (1). – 15-32.Serelaxin improves the pathophysiology of placental ischemia in the reduced uterine perfusion pressure rat model of preeclampsia / Santiago-Font J. A., Amaral L. M., Faulkner J. [et al.] // Am. J. Physiol. Regul. Integr. Comp. Physiol. – 2016. – № 1. – Р. 1158-1163.Serelaxin improves the pathophysiology of placental ischemia in the reduced uterine perfusion pressure rat model of preeclampsia / Santiago-Font J. A., Amaral L. M., Faulkner J. [et al.] // Am. J. Physiol. Regul. Integr. Comp. Physiol. – 2016. – № 1. – Р. 1158-1163.Sherwood, O. D. Relaxin. The Physiology of Reproduction, edited by Knobil E, Neill JD. – New York : Raven, 1994. – P. 861- 1009.Sherwood, O. D. Relaxin. The Physiology of Reproduction, edited by Knobil E, Neill JD. – New York : Raven, 1994. – P. 861- 1009.Okada, H. Decidualization of the human endometrium / Okada H., Tsuzuki T., Murata H. // Reprod. Med. Biol. – 2018. – Vol. 17 (3). – Р. 220-227.Okada, H. Decidualization of the human endometrium / Okada H., Tsuzuki T., Murata H. // Reprod. Med. Biol. – 2018. – Vol. 17 (3). – Р. 220-227.A Possible Ambivalent Role for Relaxin in Human Myometrial and Decidual Cells in Vitro / Baston-Büst D. M., Hess A. P., Hirchenhain J. [et al.] // Arch. Gynecol. Obstet. – 2009. – Vol. 280 (6). – Р. 961-9.A Possible Ambivalent Role for Relaxin in Human Myometrial and Decidual Cells in Vitro / Baston-Büst D. M., Hess A. P., Hirchenhain J. [et al.] // Arch. Gynecol. Obstet. – 2009. – Vol. 280 (6). – Р. 961-9.Goldsmith, L. T. Relaxin in human pregnancy / L. T. Goldsmith, G. Weiss // Ann. N. Y. Acad. Sci. – 2009. – № 1160. – Р. 130-5.Goldsmith, L. T. Relaxin in human pregnancy / L. T. Goldsmith, G. Weiss // Ann. N. Y. Acad. Sci. – 2009. – № 1160. – Р. 130-5.Relaxin regulation of endometrial structure and function in the rhesus monkey / Goldsmith L. T., Weiss G., Palejwala S. [et al.] // Proc. Natl. Acad. Sci. USA. – 2004. – № 101. – Р. 4685–4689.Relaxin regulation of endometrial structure and function in the rhesus monkey / Goldsmith L. T., Weiss G., Palejwala S. [et al.] // Proc. Natl. Acad. Sci. USA. – 2004. – № 101. – Р. 4685–4689.Decidual natural killer cells: key regulators of placental development / Croy B. A., Chantakru S., Esadeg S. [et al.] // J. Reprod. Immunol. – 2002. – № 57. – Р. 151-168.Decidual natural killer cells: key regulators of placental development / Croy B. A., Chantakru S., Esadeg S. [et al.] // J. Reprod. Immunol. – 2002. – № 57. – Р. 151-168.Production of endometrial matrix metalloproteinses, but not their tissue inhibitors, is modulated by progesterone withdrawal in an in vitro model for menstruation / Salamonsen L. A., Butt A. R., Hammond F. R. [et al.] // J. Clin. Endocrinol. Metab. – 1997. – № 82. – Р. 1409-1415.Production of endometrial matrix metalloproteinses, but not their tissue inhibitors, is modulated by progesterone withdrawal in an in vitro model for menstruation / Salamonsen L. A., Butt A. R., Hammond F. R. [et al.] // J. Clin. Endocrinol. Metab. – 1997. – № 82. – Р. 1409-1415.The microenvironment of human implantation: determinant of reproductive success / Salamonsen L.A., Evans J., Nguyen H.P. [et al.] // Am. J. Reprod. Immunol. – 2016. – № 75. – Р. 218–225.The microenvironment of human implantation: determinant of reproductive success / Salamonsen L.A., Evans J., Nguyen H.P. [et al.] // Am. J. Reprod. Immunol. – 2016. – № 75. – Р. 218–225.Associations between individual and combined polymorphisms of the TNF and VEGF genes and the embryo implantation ratin patients undergoing in vitro fertilization (IVF) programs / Boudjenah R., Molina-Gomes D., Torre A. [et al.] // PLoS One. – 2014. – № 9. – Р. e108287.Associations between individual and combined polymorphisms of the TNF and VEGF genes and the embryo implantation ratin patients undergoing in vitro fertilization (IVF) programs / Boudjenah R., Molina-Gomes D., Torre A. [et al.] // PLoS One. – 2014. – № 9. – Р. e108287.Serum relaxin levels are reduced in pregnant women with a historof recurrent miscarriage, and correlate with maternal uterine artery Doppler indices in first trimester / Anumba D. O., Gelany S., Elliott S. L. [et al.] // Eur. J. Obstet. Gynecol. Reprod. Biol. – 2009. – № 147. – Р. 41-45.Serum relaxin levels are reduced in pregnant women with a historof recurrent miscarriage, and correlate with maternal uterine artery Doppler indices in first trimester / Anumba D. O., Gelany S., Elliott S. L. [et al.] // Eur. J. Obstet. Gynecol. Reprod. Biol. – 2009. – № 147. – Р. 41-45.Implantation and pregnancy following in vitro fertilization and the effect of recombinant human relaxin administration in Macaca fascicularis / Hayes E. S., Curnow E. C., Trounson A. O. [et al.] // Biol. Reprod. – 2004. – № 71. – Р. 1591-1597.Implantation and pregnancy following in vitro fertilization and the effect of recombinant human relaxin administration in Macaca fascicularis / Hayes E. S., Curnow E. C., Trounson A. O. [et al.] // Biol. Reprod. – 2004. – № 71. – Р. 1591-1597.Relaxin gene and protein expression and its regulation of proclagenase and vascular endothelial growth factor in human endometrial cells / Palejwala S., Tseng L., Wojtczuk A [et al.] // Biol. Reprod. – 2002. – № 66. – Р. 1743-1748.Relaxin gene and protein expression and its regulation of proclagenase and vascular endothelial growth factor in human endometrial cells / Palejwala S., Tseng L., Wojtczuk A [et al.] // Biol. Reprod. – 2002. – № 66. – Р. 1743-1748.Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women / Unemori E. N., Erikson M. E., Rocco S. E. [et al.] // Hum. Reprod. – 1999. – № 1– Р. 800–806.Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women / Unemori E. N., Erikson M. E., Rocco S. E. [et al.] // Hum. Reprod. – 1999. – № 1– Р. 800–806.Relaxin deficiency results in increased expression of angiogenesis- and remodelling-related genes in the uterus of early pregnant mice but es t affect endometrial angiogenesis prior to implantation / Marshall S. A., Ng L., Unemori E. N. [et al.] // Reprod. Biol. Endocrinol. – 2016. – № 14. – Р. 11–11.Relaxin deficiency results in increased expression of angiogenesis- and remodelling-related genes in the uterus of early pregnant mice but es t affect endometrial angiogenesis prior to implantation / Marshall S. A., Ng L., Unemori E. N. [et al.] // Reprod. Biol. Endocrinol. – 2016. – № 14. – Р. 11–11.Stewart, D. R. Relaxin secretion by human granulosa cell culture is predictive of in-vitro fertilization-embryo transfer success / D. R. Stewart, C. A. VandeVoort // Hum. Reprod. – 1999. – № 14. – Р. 338-344.Stewart, D. R. Relaxin secretion by human granulosa cell culture is predictive of in-vitro fertilization-embryo transfer success / D. R. Stewart, C. A. VandeVoort // Hum. Reprod. – 1999. – № 14. – Р. 338-344.Steinetz, B. G. Progress in relaxin research. Relaxin ′94; 2nd International Congress on the Hormone Relaxin / B. G. Steinetz, R. L. Kroc, R. O. Grep. – Singapore : World Scientific, 1995. – 3 p.Steinetz, B. G. Progress in relaxin research. Relaxin ′94; 2nd International Congress on the Hormone Relaxin / B. G. Steinetz, R. L. Kroc, R. O. Grep. – Singapore : World Scientific, 1995. – 3 p.Ripening of the human cervix and induction of labor with intracervical purified porcine relaxin / MacLennan A. H., Green R. C., Grant P. [et al.] // Obstet. Gynecol. – 1986. – Vol. 68 (5). – Р. 598-601.Ripening of the human cervix and induction of labor with intracervical purified porcine relaxin / MacLennan A. H., Green R. C., Grant P. [et al.] // Obstet. Gynecol. – 1986. – Vol. 68 (5). – Р. 598-601.A randomized, double-blind, placebo-controlled trial of the safety of vaginal recombinant human relaxin for cervical ripening / Bell R. J., Permezel M., MacLennan A. [et al.] // Obstet. Gynecol. – 1993. – № 82. – Р. 328–333.A randomized, double-blind, placebo-controlled trial of the safety of vaginal recombinant human relaxin for cervical ripening / Bell R. J., Permezel M., MacLennan A. [et al.] // Obstet. Gynecol. – 1993. – № 82. – Р. 328–333.Rmbinant human relaxin as a cervical ripening agent / Brennand J. E., Calder A. A., Leitch C. R. [et al.] // Br. J. Obstet. Gynaecol. – 1997. – № 104. – Р. 775-780.Rmbinant human relaxin as a cervical ripening agent / Brennand J. E., Calder A. A., Leitch C. R. [et al.] // Br. J. Obstet. Gynaecol. – 1997. – № 104. – Р. 775-780.Recombinant human relaxin versus placebo for cervical ripening: a double-blind randomised trial in pregnant women scheduled for induction of labour / Weiss G., Teichman S., Stewart D. R. [et al.] // BMC Preg. Childbirth. – 2016. – № 16. – Р. 260.Recombinant human relaxin versus placebo for cervical ripening: a double-blind randomised trial in pregnant women scheduled for induction of labour / Weiss G., Teichman S., Stewart D. R. [et al.] // BMC Preg. Childbirth. – 2016. – № 16. – Р. 260.Malassiné, A. A comparison of placental development and endocrine functions between the human and mouse model / A. Malassiné, J. L. Frendo, D. Evain-Brion // Hum. Reprod. Update. – 2003. – № 9. – Р. 531-539.Malassiné, A. A comparison of placental development and endocrine functions between the human and mouse model / A. Malassiné, J. L. Frendo, D. Evain-Brion // Hum. Reprod. Update. – 2003. – № 9. – Р. 531-539.Plasma immunoreactive relaxin levels in pregnant and nonpregnant women / E. M. O’Byrne, B. T. Carriere, L. Sorensen [et al.] // J. Clin. Endocrinol. Metab. – 1978. – № 47. – Р. 1106-1110.Plasma immunoreactive relaxin levels in pregnant and nonpregnant women / E. M. O’Byrne, B. T. Carriere, L. Sorensen [et al.] // J. Clin. Endocrinol. Metab. – 1978. – № 47. – Р. 1106-1110.Ivell, R. Relaxin-like Peptides in Male Reproduction - A Human Perspective / R. Ivell, A. I. Agoulnik, R. Anand-Ivell // Br. J. Pharmacol. – 2017. – Vol. 174 (10). – Р. 990-1001.Ivell, R. Relaxin-like Peptides in Male Reproduction - A Human Perspective / R. Ivell, A. I. Agoulnik, R. Anand-Ivell // Br. J. Pharmacol. – 2017. – Vol. 174 (10). – Р. 990-1001.

The authors declare that there are no conflicts of interest present.